Agios Pharmaceuticals reported a net loss of $108 million for the quarter ended December 31, 2025, an increase from the $96.5 million loss recorded in the same period a year earlier. The loss widened despite a strong commercial performance, driven by a 63% revenue beat that lifted worldwide net revenue to $20.0 million, up from $10.7 million in Q4 2024.
The company’s flagship product, PYRUKYND, generated $20.0 million in global net revenue for Q4 2025, a 86% year‑over‑year increase and a 55% sequential rise from Q3 2025. This surge reflects robust demand in the U.S. market, where PYRUKYND net revenue reached $16.0 million, up from $10.7 million in Q4 2024.
Adjusted earnings per share for the quarter were a loss of $1.85, beating the consensus estimate of a $1.97 loss by $0.12, or 6.25%. The EPS beat is attributed to disciplined cost management and the higher mix of high‑margin PYRUKYND sales, which offset the company’s ongoing R&D and marketing investments.
Agios also highlighted the U.S. launch of its new product, AQVESME, approved by the FDA for treating anemia in adults with thalassemia. The launch is expected to add a second commercial revenue stream and supports the company’s transition to a product‑revenue model. Management projected U.S. PK‑deficiency revenues between $45 million and $50 million for 2026, with operating expenses expected to remain flat relative to 2025.
Market reaction to the results was positive, with analysts noting the strong revenue surprise and the company’s ability to narrow its loss per share. The revenue beat was driven by a 63% increase over consensus estimates, while the EPS beat of $0.12 per share underscored effective cost control amid expanding commercial activity.
"In 2025, we continued to execute across our portfolio, highlighted by the historic U.S. approval of AQVESME," said CEO Brian Goff. "The U.S. launch is off to a strong start, and we remain focused on expanding our PK activation franchise into additional high‑value indications while advancing our pipeline.
"Third‑quarter net PYRUKYND revenue was $12.9 million, an increase of 44% compared to $9 million in Q3 2024," CFO Cecilia Jones added, illustrating the momentum behind the company’s core product.
The company closed the year with $1.2 billion in cash, cash equivalents, and marketable securities, providing a substantial runway to fund ongoing operations, the AQVESME launch, and pipeline development.
Overall, the earnings release signals that Agios is gaining commercial traction, improving its revenue profile, and maintaining a strong cash position, while still operating at a loss as it invests in growth initiatives.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.